Table 3.
Blood analysis from mice administered once-weekly dosing of VSW1198 in combination with statin therapy (dose level -1).
| Normal range | VSW | Lov | Prav | Prav+VSW | Lov+VSW | |
|---|---|---|---|---|---|---|
| BUN | 9 to 33 | 19 ± 2.7 | 16.3 ± 1 | 16 ± 2.9 | 19.5 ± 3.1 | 14 ± 2.2 |
| CRE | 0.2 to 0.9 | 0.2 ± 0 | 0.3 ± 0.1 | <0.2 | 0.3 ± 0.1 | 0.2 ± 0.1 |
| ALT | 17 to 77 | 78.8 ± 17.9 | 53 ± 10.6 | 51.0 ± 11.3 | 322.8 ± 232.2 | 150 ± 38.8 |
| ALP | 35 to 222 | 107.8 ± 12 | 44 ± 11.2 | 55.3 ± 15 | 80 ± 40 | 73.3 ± 15.3 |
| AST | 54 to 298 | 167.5 ± 88.1 | 213.5 ± 78.6 | 172.8 ± 5.1 | 210.7 ± 174.8 | 202.3 ± 99.5 |
| TBIL | 0 to 0.9 | 0.3 ± 0 | 0.2 ± 0 | 0.4 ± 0.2 | 0.4 ± 0.1 | 0.4 ± 0 |
| GLU | 140 to 263 | 133.8 ± 16.2 | 197.5 ± 31 | 206.8 ± 21.6 | 81.3 ± 21.5 | 96.8 ± 8.8 |
| CA | 6 to 13 | 10.4 ± 0.3 | 10.7 ± 0.2 | 11.2 ± 0.2 | 11.1 ± 0.2 | 11.3 ± 0.2 |
| TP | 3.9 to 6.4 | 5.5 ± 0.3 | 5.3 ± 0.1 | 5.4 ± 0.2 | 5.9 ± 0.4 | 6.15 ± 0.2 |
| ALB | 2.5 to 4.6 | 4.6 ± 0.1 | 4.6 ± 0.2 | 4.6 ± 0.1 | 4.9 ± 0.3 | 5.0 ± 0.2 |
| GLOB | 1.2 to 2.2 | 0.9 ± 0.2 | 0.8 ± 0.1 | 0.8 ± 0.1 | 1.0 ± 0.1 | 1.3± 0.1 |
| Na | 110 to 195 | 152 ± 2.6 | 153.8 ± 2.1 | 157.5 ± 4.7 | 153.5 ± 3.3 | 148.8 ± 1 |
| K | 4 to 10.5 | 8.2 ± 0.4 | 8.0 ± 0.3 | 8.3 ± 0.2 | 8.0 ± 0.2 | 7.6 ± 0.7 |
| Cl | NR | 110 ± 2.8 | 108.3 ± 1.5 | 109 ± 1.2 | 108.5 ± 1.9 | 106 ± 1.4 |
| tCO2 | NR | 24.8 ± 0.5 | 31.8 ± 1.7 | 31.5 ± 1.7 | 25.8 ± 3.8 | 25.8 ± 1.9 |
| CK | 29.3–810 | 226.5 ± 119 | 385 ± 16.2 | 368.6 ± 17.7 | 18.7 ± 15.7 | 13.2 ± 1.3 |
Blood was collected on day 12. N=4 per group. Abbreviations: ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CA, calcium; CK, creatine kinase; Cl, chloride; CRE, creatinine; GLOB, globulin; GLU, glucose; K, potassium; LDH, lactate dehydrogenase; Lov, lovastatin; Na, sodium; NR, not reported; Prav, pravastatin; TBIL, total bilirubin; tCO2, total carbon dioxide; TP, total protein; VSW, VSW1198.